secwatch / observer
8-K filed October 20, 2023, 7:59 PM ET CIK 0001776197
other material confidence high sentiment negative materiality 0.90

AKUMIN INC.: Nasdaq/NYSE listing notice — Akumin reaches RSA with Stonepeak to go private; files prepackaged Chapter 11

AKUMIN INC.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Ronald J. Bienias

Chief Restructuring Officer
AKUMIN INC.
Effective
2023-10-20
Filed
October 20, 2023, 7:59 PM ET
Appointment of Chief Restructuring Officer Effective October 20, 2023, the board of directors of the Company appointed Ronald J. Bienias to serve as the Company’s Chief Restructuring Officer (“CRO”).

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

AKUMIN INC. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5550(b)(1)).

Exchange
nasdaq
Notice
delisting notice
Deficiency
minimum bid price
Rules
5550(a)(2), 5550(b)(1)
Exact text from the filing
h will remove the Company’s securities from being listed on Nasdaq. 2 The Staff Delisting Determination is based on the Company’s continued non-compliance with (i) the minimum bid price requirement for continued inclusion on The Nasdaq Capital Market (the “Capital Market”) under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”) and (ii) Nasdaq Listing Rule 5550(b)(1) (the “Equity Standard”), pursuant to which companies are required to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing on the Capital Market, or either of the alternatives to compliance with
View on SEC.gov
Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

AKUMIN INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1), 5550(b)(2), 5550(b)(3)).

Exchange
nasdaq
Notice
deficiency notice
Deficiency
stockholders equity
Rules
5550(b)(1), 5550(b)(2), 5550(b)(3)
Exact text from the filing
h will remove the Company’s securities from being listed on Nasdaq. 2 The Staff Delisting Determination is based on the Company’s continued non-compliance with (i) the minimum bid price requirement for continued inclusion on The Nasdaq Capital Market (the “Capital Market”) under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”) and (ii) Nasdaq Listing Rule 5550(b)(1) (the “Equity Standard”), pursuant to which companies are required to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing on the Capital Market, or either of the alternatives to compliance with
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Ronald J. Bienias was appointed as Chief Restructuring Officer at AKUMIN INC..

Action
appointed
Role
Chief Restructuring Officer
Exact text from the filing
Appointment of Chief Restructuring Officer Effective October 20, 2023, the board of directors of the Company appointed Ronald J. Bienias to serve as the Company’s Chief Restructuring Officer (“CRO”).
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

AKUMIN INC. entered into Restructuring Support Agreement with Consenting Stakeholders (Stonepeak Magnet Holdings LP, Consenting 2025 Noteholders, Consenting 2028 Noteholders, Consenting RCF Lenders, Consenting Equityholders, Consenting Non-Debtor Hospital Partner Entities, Consenting Physician-Owned Entities) (effective 2023-10-20).

Action
entry
Counterparty
Consenting Stakeholders (Stonepeak Magnet Holdings LP, Consenting 2025 Noteholders, Consenting 2028 Noteholders, Consenting RCF Lenders, Consenting Equityholders, Consenting Non-Debtor Hospital Partner Entities, Consenting Physician-Owned Entities)
Effective
2023-10-20
Exact text from the filing
On October 20, 2023, the Company, entered into a Restructuring Support Agreement (including all exhibits thereto, collectively, the “RSA”) with (i) certain of its affiliates and subsidiaries (as set forth in the RSA, and together with Akumin, the “Company Parties”); (ii) Stonepeak (iii) certain Consenting 2025 Noteholders; (iv) certain Consenting 2028 Noteholders (together with the Consenting 2025 Noteholders, the “Consenting Noteholders”); (v) certain Consenting RCF Lenders; (vi) certain Consenting Equityholders; (vii) certain Consenting Non-Debtor Hospital Partner Entities; and (viii) certain Consenting Physician-Owned Entities (as each such term is defined in the RSA, and collectively, other than the Company Parties, the “Consenting Stakeholders”).
View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR
accession 0001193125-23-259995
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.